Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
THE SCOPE OF GENE-THERAPY IN HUMANS - SCIENTIFIC, SAFETY AND ETHICAL CONSIDERATIONS
Autore:
KARPATI G; LOCHMULLER H;
Indirizzi:
MCGILL UNIV,MONTREAL NEUROL INST,NEUROMUSCULAR RES GRP,GENE THERAPY TEAM,3801 UNIV ST MONTREAL PQ H3A 2B4 CANADA
Titolo Testata:
Neuromuscular disorders
fascicolo: 5, volume: 7, anno: 1997,
pagine: 273 - 276
SICI:
0960-8966(1997)7:5<273:TSOGIH>2.0.ZU;2-D
Fonte:
ISI
Lingua:
ENG
Soggetto:
EXPRESSING TYROSINE-HYDROXYLASE; VECTOR; RECOMBINANTS; EFFICIENCY; LONG;
Keywords:
HUMAN GENE THERAPY; ETHICS; SAFETY; DESIGN;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
30
Recensione:
Indirizzi per estratti:
Citazione:
G. Karpati e H. Lochmuller, "THE SCOPE OF GENE-THERAPY IN HUMANS - SCIENTIFIC, SAFETY AND ETHICAL CONSIDERATIONS", Neuromuscular disorders, 7(5), 1997, pp. 273-276

Abstract

Gene therapy entails the introduction of specific, functional genes into cells for therapeutic or preventive purposes. Therapeutic genes may be introduced into cells in vitro (and the treated cells then introduced into the patient) or directly in vivo. Gene therapy may be used for several purposes including: (a) Gene replacement in genetic diseases; (b) Destroying malignant cells in neoplastic diseases; (c) Modifying immune responses; (d) Providing trophic molecules; (e) Immunisation against infectious diseases. In designing gene therapy strategies the following major items need to be investigated and optimised: (1) Relevant biological characteristics of the treatable cells and tissues; (2)Gene vectors (viral or non-viral); (3) The gene expression cassette (promoter + cDNA + poly A signal); (4) The safest and most effective route of administration; (5) Longevity of the transgene expression. Before human trials for gene therapy can commence for a given disease, extensive preclinical studies are to be carried out in an appropriate experimental models to assure the feasibility, safety and efficiency of the enterprise. For each disease or application, the risk/benefit ratiomust be determined. Permission by regulatory agencies, institutional review boards (IRE) and thorough informed consent are essential. Although gene therapy holds great promise for many human diseases, it is still too early to predict the extent and timetable of its successful implementation in individual diseases. (C) 1997 Elsevier Science B.V.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/03/20 alle ore 09:21:20